For the quarter ending 2026-03-31, IBO had $17K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss from operations | - | - | - | -15,631 |
| Net loss from operations | -2,284 | 5,235 | -17,105 | - |
| Depreciation and amortization | 285 | 286 | 288 | 571 |
| Stock-based compensation | 1,440 | 8 | 1 | 4 |
| Issuance of shares for professional services rendered | - | 0 | 0 | 190 |
| Accrued interest on notes payable | - | 0 | 262 | 531 |
| Change in deferred tax liability | - | -2,580 | - | - |
| Change in fair value of note payable, related party | - | -3,822 | 268 | 12,942 |
| Impairment of inventory | - | 419 | - | - |
| Loss on disposal of fixed assets | - | -12 | - | - |
| Accounts receivable | -5 | -10 | 15 | -4 |
| Inventory | - | -3 | -1 | -3 |
| Prepaid expenses and other current assets | -47 | -63 | 35 | -98 |
| Accounts payable | 27 | 607 | 22 | -159 |
| Accrued expenses | 16 | -142 | 69 | 71 |
| Net cash used by operating activities | -464 | 99 | -613 | -1,376 |
| Payments received on notes receivable | - | 1 | 1 | 1 |
| Borrowings on notes receivable | 1 | - | - | - |
| Net cash (used) provided by investing activities | -1 | 1 | 1 | 1 |
| Borrowings from related party | 482 | 184 | - | - |
| Borrowings on note payable, related party | - | - | - | 0 |
| Payments to related party | - | 293 | - | - |
| Net provided by financing activities | 482 | -109 | - | 0 |
| Net increase (decrease) in cash | 17 | -9 | -612 | -1,375 |
| Cash and cash equivalents at beginning of period | 3 | 12 | 1,999 | - |
| Cash and cash equivalents at end of period | 20 | 3 | 12 | - |
IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC. (IBO)